Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
- MMR 2023年10卷第4期 页码：461-477
- Affiliations：
1.Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
2.Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
3.Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou 310003, China
4.The Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China
5.Cancer Center, Zhejiang University, Hangzhou 310058, China
- Author bio：
* huangxing66@zju.edu.cn;
liangtingbo@zju.edu.cn
- Funds：the National Natural Science Foundation of China(31970696;81502975;82188102;81830089);Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholar(LR22H160010);National Key Research and Development Program of China(2019YFC1316000);Zhejiang Provincial Key Research and Development Program(2019C03019);Zhejiang Provincial College Student Science and Technology Innovation Activity Plan-College Student Innovation and Entrepreneurship Incubation Program (Young Talent Program)(2022R40122)
DOI：10.1186/s40779-022-00416-w
中图分类号：-
纸质出版：2023-08
- Accepted：
Scan QR Code
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine[J]. MMR, 2023,10(4):461-477.
Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9(1):53.
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine[J]. MMR, 2023,10(4):461-477. DOI： 10.1186/s40779-022-00416-w.
Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9(1):53. DOI： 10.1186/s40779-022-00416-w.
摘要
Abstract
Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity
especially in genetic alteration and microenvironment. Conventional therapeutic strategies for pancreatic cancer usually suffer resistance
highlighting the necessity for personalized precise treatment. Cancer vaccines have become promising alternatives for pancreatic cancer treatment because of their multifaceted advantages including multiple targeting
minimal nonspecific effects
broad therapeutic window
low toxicity
and induction of persistent immunological memory. Multiple conventional vaccines based on the cells
microorganisms
exosomes
proteins
peptides
or DNA against pancreatic cancer have been developed; however
their overall efficacy remains unsatisfactory. Compared with these vaccine modalities
messager RNA (mRNA)-based vaccines offer technical and conceptional advances in personalized precise treatment
and thus represent a potentially cutting-edge option in novel therapeutic approaches for pancreatic cancer. This review summarizes the current progress on pancreatic cancer vaccines
highlights the superiority of mRNA vaccines over other conventional vaccines
and proposes the viable tactic for designing and applying personalized mRNA vaccines for the precise treatment of pancreatic cancer.
关键词
Keywords
references
Klein AP . Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors . Nat Rev Gastroenterol Hepatol . 2021 ; 18 ( 7 ): 493 - 502 .
Sung H , Ferlay J , Siegel RL , Laversanne M , Soerjomataram I , Jemal A , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin . 2021 ; 71 ( 3 ): 209 - 49 .
Strobel O , Neoptolemos J , Jäger D , Büchler MW . Optimizing the outcomes of pancreatic cancer surgery . Nat Rev Clin Oncol . 2019 ; 16 ( 1 ): 11 - 26 .
Hessmann E , Buchholz SM , Demir IE , Singh SK , Gress TM , Ellenrieder V , et al . Microenvironmental determinants of pancreatic cancer . Physiol Rev . 2020 ; 100 ( 4 ): 1707 - 51 .
Conroy T , Hammel P , Hebbar M , Ben Abdelghani M , Wei AC , Raoul JL , et al . FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer . N Engl J Med . 2018 ; 379 ( 25 ): 2395 - 406 .
Von Hoff DD , Ervin T , Arena FP , Chiorean EG , Infante J , Moore M , et al . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine . N Engl J Med . 2013 ; 369 ( 18 ): 1691 - 703 .
Neoptolemos JP , Kleeff J , Michl P , Costello E , Greenhalf W , Palmer DH . Therapeutic developments in pancreatic cancer: current and future perspectives . Nat Rev Gastroenterol Hepatol . 2018 ; 15 ( 6 ): 333 - 48 .
Li E , Huang X , Zhang G , Liang T . Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy . J Exp Clin Cancer Res . 2021 ; 40 ( 1 ): 279 .
Zhang X , Huang X , Xu J , Li E , Lao M , Tang T , et al . NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1 . Nat Commun . 2021 ; 12 ( 1 ): 4536 .
Siegel RL , Miller KD , Fuchs HE , Jemal A . Cancer statistics, 2021 . CA Cancer J Clin . 2021 ; 71 ( 1 ): 7 - 33 .
Bear AS , Vonderheide RH , O'Hara MH . Challenges and opportunities for pancreatic cancer immunotherapy . Cancer Cell . 2020 ; 38 ( 6 ): 788 - 802 .
Samuel N , Hudson TJ . The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma . Nat Rev Gastroenterol Hepatol . 2011 ; 9 ( 2 ): 77 - 87 .
Makohon-Moore AP , Zhang M , Reiter JG , Bozic I , Allen B , Kundu D , et al . Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer . Nat Genet . 2017 ; 49 ( 3 ): 358 - 66 .
Yachida S , White CM , Naito Y , Zhong Y , Brosnan JA , Macgregor-Das AM , et al . Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors . Clin Cancer Res . 2012 ; 18 ( 22 ): 6339 - 47 .
Wang F , Xia X , Yang C , Shen J , Mai J , Kim HC , et al . SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy . Clin Cancer Res . 2018 ; 24 ( 13 ): 3176 - 85 .
Devico Marciano N , Kroening G , Dayyani F , Zell JA , Lee FC , Cho M , et al . BRCA-mutated pancreatic cancer: from discovery to novel treatment paradigms . Cancers . 2022 ; 14 ( 10 ): 2453 .
Emelyanova M , Pudova E , Khomich D , Krasnov G , Popova A , Abramov I , et al . Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes . Ther Adv Med Oncol . 2022 ; 14 : 17588359221083050 .
Edwards SL , Brough R , Lord CJ , Natrajan R , Vatcheva R , Levine DA , et al . Resistance to therapy caused by intragenic deletion in BRCA2 . Nature . 2008 ; 451 ( 7182 ): 1111 - 5 .
Chen A . PARP inhibitors: its role in treatment of cancer . Chin J Cancer . 2011 ; 30 ( 7 ): 463 - 71 .
Golan T , Hammel P , Reni M , Van Cutsem E , Macarulla T , Hall MJ , et al . Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer . N Engl J Med . 2019 ; 381 ( 4 ): 317 - 27 .
Javle M , Shacham-Shmueli E , Xiao L , Varadhachary G , Halpern N , Fogelman D , et al . Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials . JAMA Oncol . 2021 ; 7 ( 5 ): 693 - 9 .
Ribas A , Wolchok JD . Cancer immunotherapy using checkpoint blockade . Science . 2018 ; 359 ( 6382 ): 1350 - 5 .
Le DT , Uram JN , Wang H , Bartlett BR , Kemberling H , Eyring AD , et al . PD-1 blockade in tumors with mismatch-repair deficiency . N Engl J Med . 2015 ; 372 ( 26 ): 2509 - 20 .
Alexandrov LB , Nik-Zainal S , Wedge DC , Aparicio SAJR , Behjati S , Biankin AV , et al . Signatures of mutational processes in human cancer . Nature . 2013 ; 500 ( 7463 ): 415 - 21 .
Le DT , Durham JN , Smith KN , Wang H , Bartlett BR , Aulakh LK , et al . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade . Science . 2017 ; 357 ( 6349 ): 409 - 13 .
Stromnes IM , Hulbert A , Pierce RH , Greenberg PD , Hingorani SR . T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma . Cancer Immunol Res . 2017 ; 5 ( 11 ): 978 - 91 .
Huang X , Zhang G , Liang T . Subtyping for pancreatic cancer precision therapy . Trends Pharmacol Sci . 2022 ; 43 ( 6 ): 482 - 94 .
Moffitt RA , Marayati R , Flate EL , Volmar KE , Loeza SG , Hoadley KA , et al . Virtual microdissection identifies distinct tumor- and stromaspecific subtypes of pancreatic ductal adenocarcinoma . Nat Genet . 2015 ; 47 ( 10 ): 1168 - 78 .
Huang X , Tang T , Zhang G , Liang T . Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development . Mol Cancer . 2021 ; 20 ( 1 ): 44 .
Peng J , Sun BF , Chen CY , Zhou JY , Chen YS , Chen H , et al . Singlecell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma . Cell Res . 2019 ; 29 ( 9 ): 725 - 38 .
Chan-Seng-Yue M , Kim JC , Wilson GW , Ng K , Figueroa EF , O'Kane GM , et al . Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution . Nat Genet . 2020 ; 52 ( 2 ): 231 - 40 .
Huang X , Tang T , Zhang G , Liang T . Identification of tumor antigens and immune subtypes of cholangiocarcinoa for mRNA vaccine development . Mol Cancer . 2021 ; 20 ( 1 ): 50 .
Negahdaripour M , Golkar N , Hajighahramani N , Kianpour S , Nezafat N , Ghasemi Y . Harnessing self-assembled peptide nanoparticles in epitope vaccine design . Biotechnol Adv . 2017 ; 35 ( 5 ): 575 - 96 .
Brenner S , Jacob F , Meselson M . An unstable intermediate carrying information from genes to ribosomes for protein synthesis . Nature . 1961 ; 190 : 576 - 81 .
Lockard RE , Lingrel JB . The synthesis of mouse hemoglobin chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA . Biochem Biophys Res Commun . 1969 ; 37 ( 2 ): 204 - 12 .
Wolff JA , Malone RW , Williams P , Chong W , Acsadi G , Jani A , et al . Direct gene transfer into mouse muscle in vivo . Science . 1990 ; 247 ( 4949 Pt 1 ): 1465 - 8 .
Jirikowski GF , Sanna PP , Maciejewski-Lenoir D , Bloom FE . Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA . Science . 1992 ; 255 ( 5047 ): 996 - 8 .
Martinon F , Krishnan S , Lenzen G , Magné R , Gomard E , Guillet JG , et al . Induction of virus-specific cytotoxic T lymphocytes in vivo by liposomeentrapped mRNA . Eur J Immunol . 1993 ; 23 ( 7 ): 1719 - 22 .
Conry RM , LoBuglio AF , Loechel F , Moore SE , Sumerel LA , Barlow DL , et al . A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity . Gene Ther . 1995 ; 2 ( 1 ): 59 - 65 .
Conry RM , LoBuglio AF , Loechel F , Moore SE , Sumerel LA , Barlow DL , et al . A carcinoembryonic antigen polynucleotide vaccine for human clinical use . Cancer Gene Ther . 1995 ; 2 ( 1 ): 33 - 8 .
Hajj KA , Whitehead KA . Tools for translation: non-viral materials for therapeutic mRNA delivery . Nat Rev Mater . 2017 ; 2 : 17056 .
Kim J , Eygeris Y , Gupta M , Sahay G . Self-assembled mRNA vaccines . Adv Drug Deliv Rev . 2021 ; 170 : 83 - 112 .
Sahin U , Derhovanessian E , Miller M , Kloke BP , Simon P , Lower M , et al . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer . Nature . 2017 ; 547 ( 7662 ): 222 - 6 .
Barbier AJ , Jiang AY , Zhang P , Wooster R , Anderson DG . The clinical progress of mRNA vaccines and immunotherapies . Nat Biotechnol . 2022 ; 40 ( 6 ): 840 - 54 .
Shin MD , Shukla S , Chung YH , Beiss V , Chan SK , Ortega-Rivera OA , et al . COVID-19 vaccine development and a potential nanomaterial path forward . Nat Nanotechnol . 2020 ; 15 ( 8 ): 646 - 55 .
Chung JY , Thone MN , Kwon YJ . COVID-19 vaccines: t he status and perspectives in delivery points of view . Adv Drug Deliv Rev . 2021 ; 170 : 1 - 25 .
Pascolo S . Vaccines against COVID-19: priority to mRNA-based formulations . Cells . 2021 ; 10 ( 10 ): 2716 .
Dagan N , Barda N , Kepten E , Miron O , Perchik S , Katz MA , et al . BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting . N Engl J Med . 2021 ; 384 ( 15 ): 1412 - 23 .
Polack FP , Thomas SJ , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine . N Engl J Med . 2020 ; 383 ( 27 ): 2603 - 15 .
Baden LR , El Sahly HM , Essink B , Kotloff K , Frey S , Novak R , et al . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine . N Engl J Med . 2021 ; 384 ( 5 ): 403 - 16 .
Ali K , Berman G , Zhou H , Deng W , Faughnan V , Coronado-Voges M , et al . Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents . N Engl J Med . 2021 ; 385 ( 24 ): 2241 - 51 .
Thomas SJ , Moreira ED Jr , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months . N Engl J Med . 2021 ; 385 ( 19 ): 1761 - 73 .
Fang E , Liu X , Li M , Zhang Z , Song L , Zhu B , et al . Advances in COVID-19 mRNA vaccine development . Signal Transduct Target Ther . 2022 ; 7 ( 1 ): 94 .
Chemaitelly H , Yassine HM , Benslimane FM , Al Khatib HA , Tang P , Hasan MR , et al . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar . Nat Med . 2021 ; 27 ( 9 ): 1614 - 21 .
Choi A , Koch M , Wu K , Chu L , Ma L , Hill A , et al . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis . Nat Med . 2021 ; 27 ( 11 ): 2025 - 31 .
Tang P , Hasan MR , Chemaitelly H , Yassine HM , Benslimane FM , Al Khatib HA , et al . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar . Nat Med . 2021 ; 27 ( 12 ): 2136 - 43 .
Salman B , Zhou D , Jaffee EM , Edil BH , Zheng L . Vaccine therapy for pancreatic cancer . Oncoimmunology . 2013 ; 2 ( 12 ): e26662 .
Lepisto AJ , Moser AJ , Zeh H , Lee K , Bartlett D , McKolanis JR , et al . A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors . Cancer Ther . 2008 ; 6 ( B ): 955 - 64 .
Yanagisawa R , Koizumi T , Koya T , Sano K , Koido S , Nagai K , et al . WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study . Anticancer Res . 2018 ; 38 ( 4 ): 2217 - 25 .
Laheru D , Lutz E , Burke J , Biedrzycki B , Solt S , Onners B , et al . Allogeneic granulocyte macrophage colony-stimulating factor–secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation . Clin Cancer Res . 2008 ; 14 ( 5 ): 1455 - 63 .
Jaffee EM , Hruban RH , Biedrzycki B , Laheru D , Schepers K , Sauter PR , et al . Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation . J Clin Oncol . 2001 ; 19 ( 1 ): 145 - 56 .
Hardacre JM , Mulcahy M , Small W , Talamonti M , Obel J , Krishnamurthi S , et al . Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study . J Gastrointest Surg . 2012 ; 17 ( 1 ): 94 - 101 .
Romero P , Banchereau J , Bhardwaj N , Cockett M , Disis ML , Dranoff G , et al . The human vaccines project: a roadmap for cancer vaccine development . Sci Transl Med. 2016 . https://doi.org/10.1126/scitranslmed.aaf0685 https://doi.org/10.1126/scitranslmed.aaf0685 .
Keenan BP , Saenger Y , Kafrouni MI , Leubner A , Lauer P , Maitra A , et al . A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice . Gastroenterology . 2014 ; 146 ( 7 ): 1784-94.e6 .
Yamasaki S , Miura Y , Davydova J , Vickers SM , Yamamoto M . Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer . Int J Cancer . 2013 ; 133 ( 1 ): 88 - 97 .
Kaufman HL , Kim-Schulze S , Manson K , DeRaffele G , Mitcham J , Seo KS , et al . Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer . J Transl Med . 2007 ; 5 : 60 .
Hassan R , Thomas A , Alewine C , Le DT , Jaffee EM , Pastan I . Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol . 2016 ; 34 ( 34 ): 4171 - 9 .
Naseri M , Bozorgmehr M , Zöller M , Ranaei Pirmardan E , Madjd Z . Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy . Oncoimmunology . 2020 ; 9 ( 1 ): 1779991 .
Whiteside TL . The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy . Future Oncol . 2017 ; 13 ( 28 ): 2583 - 92 .
Xiao L , Erb U , Zhao K , Hackert T , Zoller M . Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer . Oncoimmunology . 2017 ; 6 ( 6 ): e1319044 .
Sun W , Ren Y , Lu Z , Zhao X . The potential roles of exosomes in pancreatic cancer initiation and metastasis . Mol Cancer . 2020 ; 19 ( 1 ): 135 .
Guay C , Kruit JK , Rome S , Menoud V , Mulder NL , Jurdzinski A , et al . Lymphocyte-derived exosomal microRNAs promote pancreatic β cell death and may contribute to type 1 diabetes development . Cell Metab . 2019 ; 29 ( 2 ): 348-61.e6 .
Fathollahi A , Hashemi SM , Haji Molla Hoseini M , Yeganeh F . In vitro analysis of immunomodulatory effects of mesenchymal stem cell- and tumor cell -derived exosomes on recall antigen-specific responses . Int Immunopharmacol . 2019 ; 67 : 302 - 10 .
Lee ES , Sul JH , Shin JM , Shin S , Lee JA , Kim HK , et al . Reactive oxygen species-responsive dendritic cell-derived exosomes for rheumatoid arthritis . Acta Biomater . 2021 ; 128 : 462 - 73 .
Maki RG , Livingston PO , Lewis JJ , Janetzki S , Klimstra D , Desantis D , et al . A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma . Dig Dis Sci . 2007 ; 52 ( 8 ): 1964 - 72 .
Bloch O , Crane CA , Fuks Y , Kaur R , Aghi MK , Berger MS , et al . Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial . Neuro Oncol . 2014 ; 16 ( 2 ): 274 - 9 .
Ji N , Zhang Y , Liu Y , Xie J , Wang Y , Hao S , et al . Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial . JCI Insight . 2018 ; 3 ( 10 ): e99145 .
Zhang Y , Mudgal P , Wang L , Wu H , Huang N , Alexander PB , et al . T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma . Oncoimmunology . 2020 ; 9 ( 1 ): 1749476 .
Wood C , Srivastava P , Bukowski R , Lacombe L , Gorelov AI , Gorelov S , et al . An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial . Lancet . 2008 ; 372 ( 9633 ): 145 - 54 .
Tosti G , Di Pietro A , Ferrucci PF , Testori A . HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future . Expert Rev Vaccines . 2009 ; 8 ( 11 ): 1513 - 26 .
Matsui H , Hazama S , Shindo Y , Nagano H . Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies . Expert Rev Anticancer Ther . 2018 ; 18 ( 12 ): 1205 - 17 .
Gjertsen MK , Bakka A , Breivik J , Saeterdal I , Gedde-Dahl T , Stokke KT , et al . Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study . Int J Cancer . 1996 ; 65 ( 4 ): 450 - 3 .
Gjertsen MK , Buanes T , Rosseland AR , Bakka A , Gladhaug I , Søreide O , et al . Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma . Int J Cancer . 2001 ; 92 ( 3 ): 441 - 50 .
Bernhardt SL , Gjertsen MK , Trachsel S , Møller M , Eriksen JA , Meo M , et al . Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study . Br J Cancer . 2006 ; 95 ( 11 ): 1474 - 82 .
Gunturu KS , Rossi GR , Saif MW . Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol . 2013 ; 5 ( 1 ): 81 - 9 .
Miyazawa M , Ohsawa R , Tsunoda T , Hirono S , Kawai M , Tani M , et al . Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer . Cancer Sci . 2010 ; 101 ( 2 ): 433 - 9 .
Suzuki N , Hazama S , Ueno T , Matsui H , Shindo Y , Iida M , et al . A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer . J Immunother . 2014 ; 37 ( 1 ): 36 - 42 .
Suzuki N , Hazama S , Iguchi H , Uesugi K , Tanaka H , Hirakawa K , et al . Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study . Cancer Sci . 2017 ; 108 ( 1 ): 73 - 80 .
Nishida S , Ishikawa T , Egawa S , Koido S , Yanagimoto H , Ishii J , et al . Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: a phase II randomized study . Cancer Immunol Res . 2018 ; 6 ( 3 ): 320 - 31 .
Gilliam AD , Broome P , Topuzov EG , Garin AM , Pulay I , Humphreys J , et al . An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer . Pancreas . 2012 ; 41 ( 3 ): 374 - 9 .
Rong Y , Jin D , Wu W , Lou W , Wang D , Kuang T , et al . Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine . BMC Cancer . 2009 ; 9 : 191 .
Cappello P , Rolla S , Chiarle R , Principe M , Cavallo F , Perconti G , et al . Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer . Gastroenterology . 2013 ; 144 ( 5 ): 1098 - 106 .
Cappello P , Curcio C , Mandili G , Roux C , Bulfamante S , Novelli F . Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners . Cancers . 2018 ; 10 ( 2 ): 51 .
Zhu K , Qin H , Cha SC , Neelapu SS , Overwijk W , Lizee GA , et al . Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models . Vaccine . 2007 ; 25 ( 46 ): 7955 - 61 .
Niethammer AG , Lubenau H , Mikus G , Knebel P , Hohmann N , Leowardi C , et al . Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer . BMC Cancer . 2012 ; 12 : 361 .
Fiedler K , Lazzaro S , Lutz J , Rauch S , Heidenreich R . mRNA cancer vaccines . Recent Results Cancer Res . 2016 ; 209 : 61 - 85 .
Wang Y , Zhang Z , Luo J , Han X , Wei Y , Wei X . mRNA vaccine: a potential therapeutic strategy . Mol Cancer . 2021 ; 20 ( 1 ): 33 .
Pardi N , Hogan MJ , Porter FW , Weissman D . mRNA vaccines - a new era in vaccinology . Nat Rev Drug Discov . 2018 ; 17 ( 4 ): 261 - 79 .
Grunwitz C , Kranz LM . mRNA cancer vaccines-messages that prevail . Curr Top Microbiol Immunol . 2017 ; 405 : 145 - 64 .
Alexopoulou L , Holt AC , Medzhitov R , Flavell RA . Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3 . Nature . 2001 ; 413 ( 6857 ): 732 - 8 .
Veetil AT , Zou J , Henderson KW , Jani MS , Shaik SM , Sisodia SS , et al . DNA-based fluorescent probes of NOS2 activity in live brains . Proc Natl Acad Sci U S A . 2020 ; 117 ( 26 ): 14694 - 702 .
Heil F , Hemmi H , Hochrein H , Ampenberger F , Kirschning C , Akira S , et al . Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8 . Science . 2004 ; 303 ( 5663 ): 1526 - 9 .
Tanji H , Ohto U , Shibata T , Taoka M , Yamauchi Y , Isobe T , et al . Toll-like receptor 8 senses degradation products of single-stranded RNA . Nat Struct Mol Biol . 2015 ; 22 ( 2 ): 109 - 15 .
Neefjes J , Jongsma MLM , Paul P , Bakke O . Towards a systems understanding of MHC class I and MHC class II antigen presentation . Nat Rev Immunol . 2011 ; 11 ( 12 ): 823 - 36 .
Pishesha N , Harmand TJ , Ploegh HL . A guide to antigen processing and presentation . Nat Rev Immunol . 2022 . https://doi.org/10.1038/s41577-022-00707-2 https://doi.org/10.1038/s41577-022-00707-2 .
Roche PA , Furuta K . The ins and outs of MHC class II-mediated antigen processing and presentation . Nat Rev Immunol . 2015 ; 15 ( 4 ): 203 - 16 .
Kranz LM , Diken M , Haas H , Kreiter S , Loquai C , Reuter KC , et al . Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy . Nature . 2016 ; 534 ( 7607 ): 396 - 401 .
Hasgur S , Yamamoto Y , Fan R , Nicosia M , Gorbacheva V , Zwick D , et al . Macrophage-inducible C-type lectin activates B cells to promote T cell reconstitution in heart allograft recipients . Am J Transplant . 2022 ; 22 ( 7 ): 1779 - 90 .
Wykes M , Pombo A , Jenkins C , MacPherson GG . Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response . J Immunol . 1998 ; 161 ( 3 ): 1313 - 9 .
Sahin U , Oehm P , Derhovanessian E , Jabulowsky RA , Vormehr M , Gold M , et al . An RNA vaccine drives immunity in checkpoint-inhibitortreated melanoma . Nature . 2020 ; 585 ( 7823 ): 107 - 12 .
Kauffman KJ , Webber MJ , Anderson DG . Materials for non-viral intracellular delivery of messenger RNA therapeutics . J Control Release . 2016 ; 240 : 227 - 34 .
Karikó K , Muramatsu H , Welsh FA , Ludwig J , Kato H , Akira S , et al . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability . Mol Ther . 2008 ; 16 ( 11 ): 1833 - 40 .
Tsui NBY , Ng EKO , Lo YMD . Stability of endogenous and added RNA in blood specimens, serum, and plasma . Clin Chem . 2002 ; 48 ( 10 ): 1647 - 53 .
Weide B , Carralot JP , Reese A , Scheel B , Eigentler TK , Hoerr I , et al . Results of the first phase I/II clinical vaccination trial with direct injection of mRNA . J Immunother . 2008 ; 31 ( 2 ): 180 - 8 .
Beck JD , Reidenbach D , Salomon N , Sahin U , Tureci O , Vormehr M , et al . mRNA therapeutics in cancer immunotherapy . Mol Cancer . 2021 ; 20 ( 1 ): 69 .
Heine A , Juranek S , Brossart P . Clinical and immunological effects of mRNA vaccines in malignant diseases . Mol Cancer . 2021 ; 20 ( 1 ): 52 .
Weide B , Pascolo S , Scheel B , Derhovanessian E , Pflugfelder A , Eigentler TK , et al . Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients . J Immunother . 2009 ; 32 ( 5 ): 498 - 507 .
Jackson NAC , Kester KE , Casimiro D , Gurunathan S , DeRosa F . The promise of mRNA vaccines: a biotech and industrial perspective . NPJ Vaccines . 2020 ; 5 : 11 .
Pardi N , Muramatsu H , Weissman D , Kariko K . In vitro transcription of long RNA containing modified nucleosides . Methods Mol Biol . 2013 ; 969 : 29 - 42 .
Naik R , Peden K . Regulatory considerations on the development of mRNA vaccines . Curr Top Microbiol Immunol . 2020 . https://doi.org/10.1007/82_2020_220 https://doi.org/10.1007/82_2020_220 .
Wang RF , Rosenberg SA . Human tumor antigens for cancer vaccine development . Immunol Rev . 1999 ; 170 ( 1 ): 85 - 100 .
Leko V , Rosenberg SA . Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors . Cancer Cell . 2020 ; 38 ( 4 ): 454 - 72 .
Nejo T , Yamamichi A , Almeida ND , Goretsky YE , Okada H . Tumor antigens in glioma . Semin Immunol . 2020 ; 47 : 101385 .
Li WH , Li YM . Chemical strategies to boost cancer vaccines . Chem Rev . 2020 ; 120 ( 20 ): 11420 - 78 .
Lang F , Schrörs B , Löwer M , Tureci O , Sahin U . Identification of neoantigens for individualized therapeutic cancer vaccines . Nat Rev Drug Discov . 2022 ; 21 ( 4 ): 261 - 82 .
Abelin JG , Keskin DB , Sarkizova S , Hartigan CR , Zhang W , Sidney J , et al . Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction . Immunity . 2017 ; 46 ( 2 ): 315 - 26 .
Alspach E , Lussier DM , Miceli AP , Kizhvatov I , DuPage M , Luoma AM , et al . MHC-II neoantigens shape tumour immunity and response to immunotherapy . Nature . 2019 ; 574 ( 7780 ): 696 - 701 .
Jurtz V , Paul S , Andreatta M , Marcatili P , Peters B , Nielsen M . NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data . J Immunol . 2017 ; 199 ( 9 ): 3360 - 8 .
O'Donnell TJ , Rubinsteyn A , Bonsack M , Riemer AB , Laserson U , Hammerbacher J . MHCflurry: open-source class I MHC binding affinity prediction . Cell Syst . 2018 ; 7 ( 1 ): 129-32.e4 .
Zhao W , Sher X . Systematically benchmarking peptide-MHC binding predictors: from synthetic to naturally processed epitopes . PLoS Comput Biol . 2018 ; 14 ( 11 ): e1006457 .
Blaha DT , Anderson SD , Yoakum DM , Hager MV , Zha Y , Gajewski TF , et al . High-throughput stability screening of neoantigen/HLA complexes improves immunogenicity predictions . Cancer Immunol Res . 2019 ; 7 ( 1 ): 50 - 61 .
Rasmussen M , Fenoy E , Harndahl M , Kristensen AB , Nielsen IK , Nielsen M , et al . Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity . J Immunol . 2016 ; 197 ( 4 ): 1517 - 24 .
Trolle T , Nielsen M . NetTepi: an integrated method for the prediction of T cell epitopes . Immunogenetics . 2014 ; 66 ( 7–8 ): 449 - 56 .
Weng Y , Li C , Yang T , Hu B , Zhang M , Guo S , et al . The challenge and prospect of mRNA therapeutics landscape . Biotechnol Adv . 2020 ; 40 : 107534 .
Linares- Fernández S , Lacroix C , Exposito JY , Verrier B . Tailoring mRNA vaccine to balance innate/adaptive immune response . Trends Mol Med . 2020 ; 26 ( 3 ): 311 - 23 .
Diken M , Kreiter S , Selmi A , Britten CM , Huber C , Türeci Ö , et al . Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation . Gene Ther . 2011 ; 18 ( 7 ): 702 - 8 .
Miao L , Zhang Y , Huang L . mRNA vaccine for cancer immunotherapy . Mol Cancer . 2021 ; 20 ( 1 ): 41 .
Victor MP , Acharya D , Begum T , Ghosh TC . The optimization of mRNA expression level by its intrinsic properties-Insights from codon usage pattern and structural stability of mRNA . Genomics . 2019 ; 111 ( 6 ): 1292 - 7 .
De Haro C , Méndez R , Santoyo J . The eIF-2α kinases and the control of protein synthesis 1 . FASEB J . 1996 ; 10 ( 12 ): 1378 - 87 .
Liang SL , Quirk D , Zhou A . RNase L: Its biological roles and regulation . IUBMB Life . 2006 ; 58 ( 9 ): 508 - 14 .
Batey RT , Kieft JS . Improved native affinity purification of RNA . RNA . 2007 ; 13 ( 8 ): 1384 - 9 .
Karikó K , Muramatsu H , Ludwig J , Weissman D . Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, proteinencoding mRNA . Nucleic Acids Res . 2011 ; 39 ( 21 ): e142 .
Thess A , Grund S , Mui BL , Hope MJ , Baumhof P , Fotin-Mleczek M , et al . Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals . Mol Ther . 2015 ; 23 ( 9 ): 1456 - 64 .
Weissman D , Karikó K . mRNA: fulfilling the promise of gene therapy . Mol Ther . 2015 ; 23 ( 9 ): 1416 - 7 .
Mauro VP . Codon optimization in the production of recombinant biotherapeutics: potential risks and considerations . BioDrugs . 2018 ; 32 ( 1 ): 69 - 81 .
Morrison AH , Byrne KT , Vonderheide RH . Immunotherapy and prevention of pancreatic cancer . Trends Cancer . 2018 ; 4 ( 6 ): 418 - 28 .
Ho WJ , Jaffee EM , Zheng L . The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities . Nat Rev Clin Oncol . 2020 ; 17 ( 9 ): 527 - 40 .
Hosein AN , Brekken RA , Maitra A . Pancreatic cancer stroma: an update on therapeutic targeting strategies . Nat Rev Gastroenterol Hepatol . 2020 ; 17 ( 8 ): 487 - 505 .
Danilova L , Ho WJ , Zhu Q , Vithayathil T , De Jesus-Acosta A , Azad NS , et al . Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival . Cancer Immunol Res . 2019 ; 7 ( 6 ): 886 - 95 .
Wartenberg M , Cibin S , Zlobec I , Vassella E , Eppenberger-Castori S , Terracciano L , et al . Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance . Clin Cancer Res . 2018 ; 24 ( 18 ): 4444 - 54 .
Collisson EA , Sadanandam A , Olson P , Gibb WJ , Truitt M , Gu S , et al . Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy . Nat Med . 2011 ; 17 ( 4 ): 500 - 3 .
Waddell N , Pajic M , Patch AM , Chang DK , Kassahn KS , Bailey P , et al . Whole genomes redefine the mutational landscape of pancreatic cancer . Nature . 2015 ; 518 ( 7540 ): 495 - 501 .
Bailey P , Chang DK , Nones K , Johns AL , Patch AM , Gingras MC , et al . Genomic analyses identify molecular subtypes of pancreatic cancer . Nature . 2016 ; 531 ( 7592 ): 47 - 52 .
Sivakumar S , de Santiago I , Chlon L , Markowetz F . Master regulators of oncogenic KRAS response in pancreatic cancer: an integrative network biology analysis . PLoS Med . 2017 ; 14 ( 1 ): e1002223 .
Knudsen ES , Vail P , Balaji U , Ngo H , Botros IW , Makarov V , et al . Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers . Clin Cancer Res . 2017 ; 23 ( 15 ): 4429 - 40 .
Puleo F , Nicolle R , Blum Y , Cros J , Marisa L , Demetter P , et al . Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features . Gastroenterology . 2018 ; 155 ( 6 ): 1999-2013.e3 .
Karasinska JM , Topham JT , Kalloger SE , Jang GH , Denroche RE , Culibrk L , et al . Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer . Clin Cancer Res . 2020 ; 26 ( 1 ): 135 - 46 .
Kalimuthu SN , Wilson GW , Grant RC , Seto M , O'Kane G , Vajpeyi R , et al . Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome . Gut . 2020 ; 69 ( 2 ): 317 - 28 .
Law HCH , Lagundžin D , Clement EJ , Qiao F , Wagner ZS , Krieger KL , et al . The proteomic landscape of pancreatic ductal adenocarcinoma liver metastases identifies molecular subtypes and associations with clinical response . Clin Cancer Res . 2020 ; 26 ( 5 ): 1065 - 76 .
Murphy JE , Wo JY , Ryan DP , Clark JW , Jiang W , Yeap BY , et al . Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial . JAMA Oncol . 2019 ; 5 ( 7 ): 1020 - 7 .
Hackert T , Sachsenmaier M , Hinz U , Schneider L , Michalski CW , Springfeld C , et al . Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients . Ann Surg . 2016 ; 264 ( 3 ): 457 - 63 .
Michelakos T , Pergolini I , Castillo CF , Honselmann KC , Cai L , Deshpande V , et al . Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX . Ann Surg . 2019 ; 269 ( 4 ): 733 - 40 .
Singhi AD , Wood LD . Early detection of pancreatic cancer using DNA-based molecular approaches . Nat Rev Gastroenterol Hepatol . 2021 ; 18 ( 7 ): 457 - 68 .
Fischer CG , Wood LD . From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions . J Pathol . 2018 ; 246 ( 4 ): 395 - 404 .
Huang X , Zhang G , Liang T . Pancreatic tumor initiation: the potential role of IL-33 . Signal Transduct Target Ther . 2021 ; 6 ( 1 ): 204 .
Alonso-Curbelo D , Ho YJ , Burdziak C , Maag JLV , Morris JP , Chandwani R , et al . A gene-environment-induced epigenetic program initiates tumorigenesis . Nature . 2021 ; 590 ( 7847 ): 642 - 8 .
0
浏览量
1
Downloads
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies